Humira

DRUG13 trials

Sponsors

Wright State University, LG Life Sciences, University of Illinois at Chicago, Momenta Pharmaceuticals, Inc., Boehringer Ingelheim

Conditions

Ankylosing SpondylitisAutoimmune DiseasesChronic Plaque PsoriasisCrohn DiseaseCutaneous SarcoidosisHealthy SubjectsInflammatory DiseasePlaque Psoriasis

Phase 1

Pharmacokinetics and Safety Study of LBAL in Healthy Subjects

CompletedNCT02206867

LG Life SciencesHealthy Subjects

Start: 2014-08-31End: 2015-02-28Updated: 2015-06-15

Phase 2

Safety and Efficacy Study of Humira in Treatment of Pyoderma Gangrenosum

WithdrawnNCT00730717

Wright State UniversityPyoderma Gangrenosum

Start: 2009-05-31End: 2010-12-31Updated: 2022-02-15

Efficacy Study of Humira in the Treatment of Cutaneous Sarcoidosis

WithdrawnNCT00731757

Wright State UniversityCutaneous Sarcoidosis, Sarcoidosis

Start: 2009-05-31End: 2010-12-31Updated: 2022-02-15

Personalized Therapies in Inflammatory Complex Disease

RecruitingNCT03651518

Assistance Publique - Hôpitaux de ParisAutoimmune Diseases, Inflammatory Disease

Start: 2020-10-20End: 2025-11-30Target: 32Updated: 2025-11-20

Phase 3

Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis

CompletedNCT02581345

Momenta Pharmaceuticals, Inc.Chronic Plaque Psoriasis, Psoriasis

Start: 2015-09-30End: 2017-04-04Updated: 2018-10-17

Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis

CompletedNCT02850965

Boehringer IngelheimPsoriasis

Start: 2016-08-17End: 2018-01-17Updated: 2019-02-08

BI 695501 Versus Humira in Patients With Active Crohn's Disease: a Trial Comparing Efficacy, Endoscopic Improvement, Safety, and Immunogenicity

CompletedNCT02871635

Boehringer IngelheimCrohn Disease

Start: 2016-09-28End: 2019-05-13Updated: 2020-06-04

A Phase III Study Evaluate the Efficacy and Safety of BAT1406 and Humira

CompletedNCT04135508

Bio-Thera SolutionsAnkylosing Spondylitis

Start: 2016-12-13End: 2018-05-31Updated: 2019-10-22

Study Evaluation of the Efficacy, Safety and Immunogenicity of Adalimumab in Comparison With Humira®

Mabscale, LLCPlaque Psoriasis

Start: 2023-10-02End: 2025-12-31Target: 494Updated: 2023-11-29

Phase 4

IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA

CompletedNCT02451748

University of Illinois at ChicagoRheumatoid Arthritis

Start: 2015-08-31End: 2017-12-31Updated: 2024-07-10

Unknown Phase

Safety and Efficacy of Adalimumab Therapy for Treatment of Behcet's Disease-related Uveitis in Sohag University Hospital

Sohag UniversityUveitis

Start: 2022-12-15End: 2023-12-30Target: 40Updated: 2023-01-13

IKBKB Gene Polymorphism (Single Nucleotide Polymorphism) (SNP) in Psoriatic and Psoriatic Arthritis Patients

CompletedNCT06729463

South Valley UniversityPsoriasis, Psoriatic Arthritis

Start: 2024-12-01End: 2025-03-30Updated: 2025-08-14

Evaluation of IL 12B Genetic Polymorphism (rs3213094)

RecruitingNCT07128472

South Valley UniversityPsoriasis

Start: 2025-08-01End: 2026-02-01Target: 40Updated: 2025-08-19

Related Papers

Summary of Research: Immunogenicity of Adalimumab Reference Product and Adalimumab-adbm in Patients with Rheumatoid Arthritis, Crohn's Disease, and Chronic Plaque Psoriasis: A Pooled Analysis of the VOLTAIRE trials.

2025-06-11

Immunogenicity of adalimumab reference product and adalimumab-adbm in patients with rheumatoid arthritis, Crohn’s disease and chronic plaque psoriasis: a pooled analysis of the VOLTAIRE trials

BMJ Open2024-11-012 citations

Safety and efficacy of BI 695501 versus adalimumab reference product in patients with advanced Crohn's disease (VOLTAIRE-CD): a multicentre, randomised, double-blind, phase 3 trial.

2021-08-1134 citations

Similar efficacy, safety, and immunogenicity of the biosimilar BI 695501 and adalimumab reference product in patients with moderate-to-severe chronic plaque psoriasis: results from the randomized Phase III VOLTAIRE-PSO study

Expert Opinion on Biological Therapy2020-12-1520 citations

P052 Biosimilar BI 695501 Demonstrates Non-Inferior Efficacy and Comparable Safety to Adalimumab Reference Product in Patients With Active Crohn's Disease

The American Journal of Gastroenterology2019-12-01

Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study

Annals of the Rheumatic Diseases2018-03-07112 citations